{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:47:26Z","timestamp":1783648046003,"version":"3.55.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>Two patients presented with Cushing's syndrome due to ectopic ACTH secretion. Initial localization studies included computed tomography, magnetic resonance imaging, and octreoscans (111In-pentreotide scintigraphy), which were negative in both patients. They were treated with the glucocorticoid receptor antagonist mifepristone, with improvement in their clinical symptoms. Follow-up octreoscans after, respectively, 6 and 12 months showed the unequivocal presence of a bronchial carcinoid in both patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The objective of the study was to correlate in vivo and in vitro findings in patients with ectopic ACTH-producing syndrome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>We determined the expression of somatostatin and dopamine receptors by immunohistochemistry (patients 1 and 2), quantitative PCR, and in vitro culturing of tumor cells (patient 1 only).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>In Vitro Results:<\/jats:title>\n                  <jats:p>Both tumors were strongly positive for somatostatin receptor type 2 (sst2) on immunohistochemistry, whereas one of the tumors (patient 1) was also dopamine receptor subtype 2 (D2) positive on both immunohistochemistry and quantitative PCR. Octreotide (a sst2 preferring analog) and cabergoline (D2 agonist) both decreased the ACTH levels in the cultured tumor cells of patient 1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>We describe two patients with ACTH-producing bronchial carcinoids, in whom a direct down-regulatory effect of glucocorticoid levels on tumoral sst2 receptor expression is suggested by a remarkable change in octreoscan status after successful mifepristone therapy. Further studies will have to demonstrate whether glucocorticoid lowering or antagonizing therapy may be used to improve the diagnostic accuracy of somatostatin receptor scintigraphy in patients with ectopic ACTH production of unknown primary origin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2011-1264","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T11:37:45Z","timestamp":1321529865000},"page":"455-462","source":"Crossref","is-referenced-by-count":45,"title":["Mifepristone Effects on Tumor Somatostatin Receptor Expression in Two Patients with Cushing's Syndrome due to Ectopic Adrenocorticotropin Secretion"],"prefix":"10.1210","volume":"97","author":[{"given":"C.","family":"de Bruin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine (C.d.B., L.J.H., P.M.v.K., A.M.W., D.M.S.-M., S.W.J.L., W.W.d.H., R.A.F.), 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. J.","family":"Hofland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (C.d.B., L.J.H., P.M.v.K., A.M.W., D.M.S.-M., S.W.J.L., W.W.d.H., R.A.F.), 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. K.","family":"Nieman","sequence":"additional","affiliation":[{"name":"Pediatric and Reproductive Endocrinology Branch (L.K.N.), National Institutes of Health, Bethesda, Maryland 20892-1109"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"van Koetsveld","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (C.d.B., L.J.H., P.M.v.K., A.M.W., D.M.S.-M., S.W.J.L., W.W.d.H., R.A.F.), 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Waaijers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (C.d.B., L.J.H., P.M.v.K., A.M.W., D.M.S.-M., S.W.J.L., W.W.d.H., R.A.F.), 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Sprij-Mooij","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (C.d.B., L.J.H., P.M.v.K., A.M.W., D.M.S.-M., S.W.J.L., W.W.d.H., R.A.F.), 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Essen","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, and Department of Nuclear Medicine (M.v.E.), Erasmus Medical Center, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. W. J.","family":"Lamberts","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (C.d.B., L.J.H., P.M.v.K., A.M.W., D.M.S.-M., S.W.J.L., W.W.d.H., R.A.F.), 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W.","family":"de Herder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (C.d.B., L.J.H., P.M.v.K., A.M.W., D.M.S.-M., S.W.J.L., W.W.d.H., R.A.F.), 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Feelders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (C.d.B., L.J.H., P.M.v.K., A.M.W., D.M.S.-M., S.W.J.L., W.W.d.H., R.A.F.), 3015 CE Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616140430200_B1","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1210\/jc.2004-2527","article-title":"Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health.","volume":"90","author":"Ilias","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing's syndrome.","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"key":"2020071616140430200_B3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1210\/jc.2005-1542","article-title":"The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.","volume":"91","author":"Isidori","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B4","first-page":"20","article-title":"Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor.","volume":"78","author":"Phlipponneau","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1210\/jcem-68-5-988","article-title":"Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide.","volume":"68","author":"Bertagna","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B6","first-page":"17","article-title":"A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome.","volume":"78","author":"Lamberts","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1210\/jc.2006-0728","article-title":"Dopamine receptor expression and function in corticotroph ectopic tumors.","volume":"92","author":"Pivonello","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0002-9343(94)90059-0","article-title":"Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion.","volume":"96","author":"de Herder","year":"1994","journal-title":"Am J Med"},{"key":"2020071616140430200_B9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1210\/jcem.84.4.5583","article-title":"Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.","volume":"84","author":"Tabarin","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B10","first-page":"1184","article-title":"Tumor localization\u2014the ectopic ACTH syndrome.","volume":"84","author":"de Herder","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B11","first-page":"1780","article-title":"Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.","volume":"82","author":"Aron","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1677\/JME-08-0110","article-title":"Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.","volume":"42","author":"de Bruin","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"2020071616140430200_B13","first-page":"E278","article-title":"Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.","volume":"289","author":"van der Hoek","year":"2005","journal-title":"Am J Physiol"},{"key":"2020071616140430200_B14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000072798","article-title":"Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects.","volume":"78","author":"Park","year":"2003","journal-title":"Neuroendocrinology"},{"key":"2020071616140430200_B15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","article-title":"Octreotide exerts different effects in vivo and in vitro in Cushing's disease.","volume":"130","author":"Stalla","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"2020071616140430200_B16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-2265.2011.04130.x","article-title":"Rapid decrease in adrenal responsiveness to ACTH stimulation after successful pituitary surgery in patients with Cushing's disease.","volume":"75","author":"Alwani","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616140430200_B18","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR.","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"2020071616140430200_B19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1210\/jcem.84.2.5497","article-title":"Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors.","volume":"84","author":"Hofland","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0303-7207(99)00161-6","article-title":"Genomic structure and transcriptional regulation of the human somatostatin receptor type 2.","volume":"157","author":"Petersenn","year":"1999","journal-title":"Mol Cell Endocrinol"},{"key":"2020071616140430200_B21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071616140430200_B22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2008-2101","article-title":"Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.","volume":"94","author":"de Bruin","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B23","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.","volume":"91","author":"Batista","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B24","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1172\/JCI117143","article-title":"Human small cell lung cancer cell lines expressing the proopiomelanocortin gene have aberrant glucocorticoid receptor function.","volume":"93","author":"Ray","year":"1994","journal-title":"J Clin Invest"},{"key":"2020071616140430200_B25","first-page":"1193","article-title":"Glucocorticoid receptor structure and function in an adrenocorticotropin-secreting small cell lung cancer.","volume":"9","author":"Gaitan","year":"1995","journal-title":"Mol Endocrinol"},{"key":"2020071616140430200_B26","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1210\/jc.2003-030525","article-title":"A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing's syndrome.","volume":"88","author":"Tsagarakis","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1210\/jc.2009-2282","article-title":"Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors.","volume":"95","author":"Zemskova","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B28","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1210\/jcem-67-5-1080","article-title":"Successful treatment with SMS 201-995 of Cushing's syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma.","volume":"67","author":"Lamberts","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616140430200_B29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","article-title":"Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome.","volume":"10","author":"de Bruin","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"key":"2020071616140430200_B30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance.","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"2020071616140430200_B31","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJM200506093522322","article-title":"Cabergoline plus lanreotide for ectopic Cushing's syndrome.","volume":"352","author":"Pivonello","year":"2005","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/2\/455\/10412797\/jcem0455.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/2\/455\/10412797\/jcem0455.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:10:29Z","timestamp":1594955429000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/97\/2\/455\/2836332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2011-1264","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,1]]}}}